{"nctId":"NCT00257010","briefTitle":"A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches","startDateStruct":{"date":"2005-12"},"conditions":["Migraine"],"count":447,"armGroups":[{"label":"Almotriptan Malate","type":"EXPERIMENTAL","interventionNames":["Drug: Almotriptan Malate"]}],"interventions":[{"name":"Almotriptan Malate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a history of migraine for at least one year\n* Have an average of 1 - 14 migraines per month for the 6 months prior to study entry\n* Able to swallow oral medication\n* Able to complete a headache diary\n* Only taking one migraine preventive medication and on the same dose of that medication for at least 30 days before entering the study)\n\nExclusion Criteria:\n\n* Have an allergy to almotriptan malate or have stopped taking almotriptan malate due to side effects\n* Have 15 or more days within a month in which you have a headache\n* Usually experience migraine aura (most common symptoms being visual disturbances or tingling sensations before migraine pain begins) without a headache\n* Experience more than 6 non-migraine headaches per month","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Pain Free Headaches at 2 and 24 Hours Post-Dose","description":"Headache pain free is defined as a decrease in baseline pain intensity from severe, moderate or mild to no pain, without the use of supplemental pain medication and/or anti-emetic medication (including a second dose of study medication) within 2 (or 24) hours of first dose of study medication. Sustained pain free is defined as pain free at 2 and 24 hours without the use of supplemental pain medication and/or anti-emetic medication (including a second dose of study medication) within 24 hours.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3218","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5236","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3048","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Headaches Achieving Pain Relief at 2 and 24 Hours Post-Dose","description":"Headache pain relief is defined as a decrease in baseline pain intensity from either severe or moderate intensity to mild or no pain, without the use of supplemental pain medication and/or anti-emetic medication (including a second dose of study medication) within 2 (or 24) hours of first dose of study medication. Sustained pain relief is defined as pain relief at 2 and 24 hours without the use of supplemental pain medication and/or anti-emetic medication (including a second dose of study medication) within 24 hours.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3765","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4182","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3384","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Headaches With Photophobia","description":"Occurrence and intensity of photophobia post-dose of study medication. Photophobia is an abnormal sensitivity to or intolerance of light, especially by the eyes.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3150","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"936","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Headaches With Phonophobia","description":"Occurrence and intensity of phonophobia post-dose of study medication. Phonophobia is an abnormal sensitivity to or intolerance of noise.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5783","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2847","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"805","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Headaches With Nausea","description":"Occurrence and intensity of nausea post-dose of study medication. Nausea is a feeling of sickness characterized by gastrointestinal distress and an urge to vomit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3262","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1785","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"542","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Headaches With Vomiting","description":"Occurrence and intensity of vomiting post-dose of study medication. Vomiting is an act or instance of disgorging the contents of the stomach through the mouth also called emesis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"357","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"258","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":420},"commonTop":["Nasopharyngitis","Sinusitis","Upper Respiratory Tract Infection","Pharyngolaryngeal Pain","Nausea"]}}}